Qube Research & Technologies (QRT)
MYGN icon

Qube Research & Technologies (QRT)’s Myriad Genetics MYGN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.51M Sell
1,665,835
-24,626
-1% -$112K 0.01% 1316
2026
Q1 		$7.61M Buy
1,690,461
+817,335
+94% +$4.26M 0.01% 1445
2025
Q4 		$5.37M Sell
873,126
-313,381
-26% -$2.27M 0.01% 1727
2025
Q3 		$8.58M Sell
1,186,507
-865,081
-42% -$5.14M 0.01% 1423
2025
Q2 		$10.9M Buy
2,051,588
+633,439
+45% +$3.74M 0.01% 1238
2025
Q1 		$12.6M Buy
1,418,149
+416,776
+42% +$5.01M 0.01% 990
2024
Q4 		$13.7M Buy
1,001,373
+492,749
+97% +$9.09M 0.02% 907
2024
Q3 		$13.9M Buy
508,624
+437,847
+619% +$11.9M 0.02% 836
2024
Q2 		$1.73M Buy
+70,777
New +$1.55M ﹤0.01% 1698
2024
Q1 		– Sell
-19,070
Closed -$365K – 4732
2023
Q4 		$365K Sell
19,070
-112,483
-86% -$1.95M ﹤0.01% 2467
2023
Q3 		$2.11M Buy
131,553
+113,000
+609% +$2.15M 0.01% 1355
2023
Q2 		$430K Buy
+18,553
New +$405K ﹤0.01% 1553
2022
Q3 		– Sell
-18,025
Closed -$328K – 2832
2022
Q2 		$328K Buy
+18,025
New +$374K ﹤0.01% 1558

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MYGN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Myriad Genetics (MYGN) stake by 1.5% in Q2 2026, selling an estimated $112K and leaving 1,665,835 shares worth $9.51M. The position accounts for 0.01% of the portfolio, ranked #1316.

Qube Research & Technologies (QRT) first reported a position in MYGN in Q2 2022 and has held it in 13 quarters since. The position peaked at $13.9M in Q3 2024. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 1,665,835 shares of Myriad Genetics worth $9.51M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 24,626 Myriad Genetics shares in Q2 2026, an estimated $112K.
  • Myriad Genetics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1316 holding.
  • Qube Research & Technologies (QRT) first reported a position in Myriad Genetics in Q2 2022 and has held it in 13 quarters since.
  • Qube Research & Technologies (QRT)'s Myriad Genetics position peaked at $13.9M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.